Clinical Trials Logo
  1. Home
  2. Chemotherapy
  3. NCT05560516
  4. Details
NCT05560516 Clinical Trial

Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)

Chemotherapy-induced Peripheral Neuropathy Clinical Trial

— QULOX  

Official title:
A Comparison Between Qutenza and Duloxetine for the Treatment of Painful Chemotherapy-induced Peripheral Neuropathy: a Pragmatic Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05560516
Other study ID # NL79669.029.21
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 1, 2022
Est. completion date December 31, 2025

Study information
Verified date December 2023
Source Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Contact Emma Cassee
Phone +31643949251
Email e.cassee@amsterdamumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to determine whether in patients with CIPN pain, treatment with Qutenza has the same effect as treatment with duloxetine 60 mg daily.

Description:

Rationale: Painful polyneuropathy occurs in approximately 20-40% of patients after the chemotherapy treatment and has a negative influence on quality of life. To our knowledge, no previous randomized study examined Qutenza in patients with CIPN, and no study compared Qutenza to duloxetine. We hypothesize that the effect of Qutenza on the severity of pain and its impact on functioning is the same as that of duloxetine in patients with CIPN, as measured by the numeric rating scale (NRS). Objective: The primary objective is to determine whether in patients with CIPN pain, treatment with Qutenza has the same effect as treatment with duloxetine 60 mg daily. Study design: The study is a pragmatic randomized controlled trial. Study population: Patients who have been treated with chemotherapy in the last 5 years to 3 months and with CIPN grade 1 or higher according to the NCIC-CTC (National Cancer Institute of Canada-Common Toxicity Criteria). The patients are ≥ 18 years of age and have to experience painful neuropathy longer than 3 months with mean (1 week) pain score of ≥4. Intervention: The affected extremity or extremities will be treated with Qutenza (179mg) according to normal procedures of the hospital and as recommended by the manufacturer. Patients randomized to duloxetine will start with duloxetine 30 mg per day. After 1 week the dose of duloxetine will be increased, if tolerated, to 60 mg per day for a period of 12 weeks. Main study parameters/endpoints: The primary endpoint will be average pain reduction at week 12 after start of treatment as measured by the NRS (Numeric Rating Scale). Furthermore secondary objectives will be: pain interference as measured by the BPI (Brief Pain Inventory), side effect profile, quality of life, patient satisfaction, pain at 6 weeks after the start of treatment. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Patients will visit the research location for a screening visit to determine whether the patient fits the in- and exclusion criteria. After the baseline visit patients will be randomized to either receive Qutenza or duloxetine. All patients will fill in questionnaires (either digital or on paper) before starting treatment with Qutenza or duloxetine (T=0), after 6 weeks of treatment (T=6) and after 12 weeks of treatment (T=12) to obtain the primary and secondary endpoints. All patients will be followed for a total period of 12 weeks. In the first week of treatment patients fill in a questionnaire with side effect profile on a daily basis after 2 weeks patients will fill in a questionnaire on a weekly base. Castor will be used to send the 'side effect questionnaire'. Since both treatments are commonly used in the treatment of neuropathic pain and are both registered for that indication, no serious complications and no additional burden other than normal treatment are expected.

Recruitment information / eligibility
Status Recruiting
Enrollment 102
Est. completion date December 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years of age - Presence of CIPN grade 1 or higher according to the NCIC-CTC - Mean pain (1 week) score of = 4 - Treatment with chemotherapy in the last 5 years - Able to give oral and written informed consent - Painful neuropathy longer than three months Exclusion Criteria: - Peripheral neuropathy from other causes (e.g. carpal/tarsal tunnel syndrome, radiculopathy, spinal stenosis, brachial plexopathy) - Leptomeningeal carcinomatosis - Severe depression or use of anti-depressant medication - Psychiatric disorders which can interfere with cooperation - Abnormal renal (< GFR 30) or liver function tests (> 2 times normal value) - Severe heart failure as determined by the cardiologist - Allergy for duloxetine or capsaicin - Skin diseases in hands and/or feet, damaged skin - The presence of uncontrolled/untreated hypertension - Concomitant use of medication that may interact with duloxetine such as fluvoxamine, ciprofloxacin and enoxacin - Active cancer treatment (such as radiotherapy or chemotherapy) - Active cancer - Previous treatment with Qutenza or duloxetine for CIPN - Any condition that by the judgement of the investigator might interfere with the investigation

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Qutenza
Capsaicine patch: Qutenza 8% patch will be applied to the skin according to the instruction of the manufacturer. After application of local anesthetics on the skin, a Qutenza 8% patch will be placed. 1-4 patches will be placed and can be adjusted to the right size, depending on the surface of the CIPN. The patch(es) will be removed after 30-60 minutes. The effect will last about 12 weeks.
• Duloxetine
Duloxetine tablets: In week 1 patients will receive 30 mg duloxetine one time per day. In week 2 the dose will be increased to 60 mg one time per day. In case of inacceptable adverse events the patient is allowed to reduce the dose to 30 mg one time per day after consultation with the researcher or physician.

Locations
Country Name City State
Netherlands Amsterdam UMC, locatie VUMC Amsterdam

Sponsors (3)
Lead Sponsor Collaborator
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Leiden University Medical Center, Reinier de Graaf

Country where clinical trial is conducted

Netherlands, 

Outcome
Type Measure Description Time frame Safety issue
Primary Average pain change As measured by the Brief Pain Inventory, a scale from 0 to 10, with 0 is no pain at all, and 10 is worst pain you can imagine 12 weeks
Secondary Pain interference score Measured by the Brief Pain Inventory, a scale from 0 to 10, with 0 is no pain at all, and 10 is worst pain you can imagine 12 weeks
Secondary Quality of life score Measured by EuroQol-5D-5L: The descriptive system comprises 5 dimensions: mobility, self care, usual activities, pain/discomfort, anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The respondent is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions 12 weeks
Secondary Side effect profile Measured by patient diary, open to fill in what side effects patients experienced 12 weeks
Secondary Patient satisfaction Measured by Global perceived effect score, a scale from 1 to 7, with recovery scale 1 means much better and 7 means pain got worse 12 weeks
Secondary Pain at 6 weeks after the start of treatment Measured by Brief Pain Inventory, a scale from 0 to 10, with 0 is no pain at all, and 10 is worst pain you can imagine 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05528263 - Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial) N/A
Completed NCT03272919 - Chemotherapy Induced Peripheral Neuropathy (CIPN) N/A
Not yet recruiting NCT06430814 - Clinical Biomarker of Paclitaxel-induced Peripheral Neuropathy
Not yet recruiting NCT05840562 - Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy Phase 3
Completed NCT02553863 - The Effectiveness and Cost-effectiveness of Acupuncture in Managing Chemotherapy-induced Peripheral Neuropathy N/A
Recruiting NCT04786977 - Physiologic Measure of VIPN
Completed NCT03655587 - Impact of an Orthotic Intervention in Children With Peripheral Neuropathy N/A
Completed NCT03687970 - A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN) N/A
Terminated NCT04770402 - Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients N/A
Completed NCT03254394 - Lidocaine for Oxaliplatin-induced Neuropathy Phase 1/Phase 2
Completed NCT04367480 - Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy N/A
Recruiting NCT04237194 - A New Diagnostic Method to Assess Paclitaxel-Induced Peripheral Neuropathy
Completed NCT04843410 - Effect of Exercise in the Management of Peripheral Neuropathy N/A
Terminated NCT03782402 - Cannabinoids for Taxane Induced Peripheral Neuropathy Phase 2
Not yet recruiting NCT06389721 - Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
Recruiting NCT05121558 - The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy) Phase 3
Withdrawn NCT04492436 - A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo Phase 2
Not yet recruiting NCT03112057 - Visualize Nociceptor Changes in Neuropathic Human N/A
Completed NCT04262778 - Diagnostic of Chemotherapy Induced Neuropathy in Children
Recruiting NCT06324344 - Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN) N/A

External Links